title: Voriconazole.
abstract: Voriconazole (VRZ) is a second-generation triazole antifungal agent active against many species of Aspergillus and Candida and acts by inhibiting ergosterol synthesis. VRZ has less nephrotoxicity and less infusion-related toxicity than that of Amphotericin B. Oral and parental formulation have similar pharmacokinetics and thus oral formulation shortens the duration of hospital stay. It is overall well tolerated but has significant drug interactions.
authors.affiliation: Department of Hematology, All India Institute of Medical Sciences, New Delhi 110 029, India. dr_rahul6@hotmail.com
authors.forename: Rahul
authors.initials: R
authors.lastname: Naithani
authors.forename: Rajat
authors.initials: R
authors.lastname: Kumar
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D004347:Drug Interactions; D006801:Humans; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole